can you take aod 9604 with tirzepatide vs Tirzepatide: Which Peptide Wins for Weight Loss? AOD 9604 Alternatives for Weight

The 85 to 91% of patients who hit at least 5% weight loss in SURMOUNT-1 were all on injections

Patients sometimes report: Reduced cravings between meals Smaller portion sizes Improved awareness of fullness For individuals starting Mounjaro for weight loss, these early appetite changes often help establish healthier eating patterns

While not dangerous, it was unexpected and is something researchers will continue monitoring in ongoing trials

A: Gastrointestinal discomfort stands as the dominant adverse response of GLP-1 agonists, including mild nausea, transient vomiting, bloating, diarrhea or constipation, which mostly emerge within the initial 28 weeks of administration as the gastrointestinal tract adapts to delayed emptying effects

Given the increasing interest in the potential use of incretins in cardiovascular diseases, conducting randomized controlled trials in this direction is warranted